A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

Inclusion Criteria: * Have no significant body weight change for the 3 months prior to screening Part A and Part E: * Are considered healthy * Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening Part B: * Have a BMI of 27 to 45 kg/m2 at screening Part C: * Have a BMI of 25 to 45 kg/m2 at screening Part D: * Have type 2 diabetes * Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening * Have a BMI of 27 to 45 kg/m2 at screening Exclusion Criteria: * Have had an acute cardiovascular condition within the past 6 months prior to screening * Have liver disease or pancreatitis * Have used medications for weight loss within the 3 months prior to screening Parts A, B, C, E: * Have any form of diabetes Part D: * Have type 1 diabetes